Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.94 USD
+0.10 (0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $83.81 -0.13 (-0.15%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Gilead Sciences (GILD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$83.63 | $119.00 | $69.00 | -0.25% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Gilead Sciences comes to $83.63. The forecasts range from a low of $69.00 to a high of $119.00. The average price target represents a decline of 0.25% from the last closing price of $83.84.
Analyst Price Targets (24)
Broker Rating
Gilead Sciences currently has an average brokerage recommendation (ABR) of 2.07 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 2.07 a month ago based on 27 recommendations.
Of the 27 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 44.44% and 3.7% of all recommendations. A month ago, Strong Buy made up 44.44%, while Buy represented 3.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 11 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 14 | 14 | 14 | 14 | 14 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.07 | 2.07 | 2.07 | 2.12 | 2.12 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/29/2024 | SVB Securities | Daina M Graybosch | Hold | Hold |
8/15/2024 | Truist Securities | Asthika S Goonewardene | Hold | Hold |
8/15/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
8/9/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
8/9/2024 | Not Identified | Not Identified | Hold | Hold |
8/9/2024 | Evercore Partners | Umer Raffat | Not Available | Strong Buy |
8/9/2024 | Not Identified | Not Identified | Hold | Hold |
8/8/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
7/24/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
7/22/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
7/8/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
6/26/2024 | Atlantic Equities | Simon Baker | Not Available | Strong Buy |
6/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/20/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Hold |
5/1/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/24/2024 | Not Identified | Not Identified | Moderate Sell | Hold |
3/29/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
3/4/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
2/22/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/7/2024 | UBS | Colin N Bristow | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.07 |
ABR (Last week) | 2.07 |
# of Recs in ABR | 27 |
Average Target Price | $83.63 |
LT Growth Rate | 7.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | 1.66 |
GILD FAQs
Gilead Sciences, Inc. (GILD) currently has an average brokerage recommendation (ABR) of 2.07 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms.
The average price target for Gilead Sciences, Inc. (GILD) is $83.63. The current on short-term price targets is based on 12 reports.
The forecasts for Gilead Sciences, Inc. (GILD) range from a low of $69 to a high of $119. The average price target represents a decline of $0.25 from the last closing price of $83.84.
The current DOWNSIDE for Gilead Sciences, Inc. (GILD) is 0.25%
Based on short-term price targets offered by 24 analysts, the average price target for Gilead Sciences comes to $83.63. The forecasts range from a low of $69.00 to a high of $119.00. The average price target represents a decline of 0.25% from the last closing price of $83.84.